China has granted conditional commercial approval for two COVID-19 vaccines, and six of 16 vaccines given emergency permission for clinical trials have entered Phase 3 trials, the National Medical Products Administration (NMPA) said Friday.

The regulatory body said it has given conditional commercial approval for two drugs and permitted clinical trials of 22 drugs for treating and preventing COVID-19 and related indications.

The NMPA has also issued emergency authorization to 54 test reagents for the novel coronavirus. It said China has reached a daily capacity of manufacturing reagents to test over 24 million people.